The CRISPR tool was successfully used to correct a genetic defect in cells affected by chronic granulomatous disease. However, the repair process also introduced new genetic defects, highlighting the need for caution when using CRISPR technology in clinical settings.
A study published in the Journal of Clinical Investigation identifies Olfm4 as a potential therapeutic target for Chronic Granulomatous Disease (CGD) patients. Deletion of Olfm4 in mouse models protected against Staphylococcus aureus infections, including community-associated MRSA strains.
A new clinical trial shows that antifungal prophylaxis with itraconazole reduces fungal infection risk in children with chronic granulomatous disease (CGD). The study found a statistically significant reduction in cases, suggesting the addition of itraconazole to treatment regimens.